XCancer

68Ga-NYM215 in NENs

Description:

This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms. An head-to-head comparison with 68Ga-DOTATATE PET/CT will assess the diagnostic performance of 68Ga-NYM215 PET/CT at both the patient and lesion levels.

Sponsor:

Peking Union Medical College Hospital

Phase:

Phase 1/2

Contacts:

Meixi Liu, MD (CONTACT)

meixiliu_pumc@126.com

+86-15010405355

Huo Li, MD (CONTACT)

huoli@pumch.cn

+86-13910801986

Government Study Link:

NCT07835906 - Click here to see study on

ClinicalTrials.gov

NYM215

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides

DOTATATE

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA
Inclusion
  • At least one suspected lesion based on other imaging findings or clinical assessment.
  • Histopathologically confirmed neuroendocrine tumor.
Exclusion
  • Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR#30ml/min).
  • Inability to undergo PET/CT imaging.
  • Combined with other types of tumors.